Genetic predisposition to papillary thyroid carcinoma is mediated by a long non-coding RNA TINCR enhancer polymorphism

Int Immunopharmacol. 2022 Aug:109:108796. doi: 10.1016/j.intimp.2022.108796. Epub 2022 Apr 27.

Abstract

Single nucleotide polymorphisms (SNPs) in the enhancer region have been demonstrated to confer to altered enhancer activities, aberrant gene expression, and cancer susceptibility. In this study, we aimed to examine the association between an SNP, rs8101923, within terminal differentiation-induced non-coding RNA (TINCR) and the risk of papillary thyroid carcinoma (PTC). Blood samples from 559 patients with PTC and 445 healthy individuals were collected. The rs8101923 was genotyped by using polymerase chain reaction-restriction fragment length polymorphism assay. The impact of the rs8101923 on TINCR expression and enhancer activity was evaluated by quantitative real-time PCR and dual-luciferase reporter assay. The binding of AP-2α to TINCR enhancer was determined by chromatin immunoprecipitation. The rs8101923 G allele was significantly associated with a higher risk of PTC (adjusted OR = 1.37; 95% CI: 1.15-1.64). Mechanistically, the rs8101923 was related to increased transcriptional levels and enhancer activities (P < 0.05). Transcription factor AP-2α binds to the enhancer region of TINCR containing the rs8101923 locus, and promotes cell proliferation in PTC. These findings suggest the rs8101923 as a risk factor in the pathogenesis of PTC, which provides evidence for explaining the mechanism of the rs8101923 risk allele predisposing to PTC.

Keywords: Enhancer; Papillary thyroid carcinoma; Polymorphism; Terminal differentiation-induced non-coding RNA; Transcription factor.

MeSH terms

  • Carcinoma, Papillary* / genetics
  • Genetic Predisposition to Disease
  • Humans
  • Polymorphism, Single Nucleotide
  • RNA, Long Noncoding* / genetics
  • Thyroid Cancer, Papillary / genetics
  • Thyroid Neoplasms* / genetics

Substances

  • RNA, Long Noncoding
  • TINCR lncRNA, human